Cardiovascular Death
8
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (8)
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events
Emulation of the Moderate Alcohol and Cardiovascular Health Trial (MACH15)
Construction of a Cohort for Pan-Vascular Disease Among Employees of Taizhou People's Hospital
ACS Registry - A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow
BioFreedom™ BA9™ Ultra
A Prospective Multicenter Study to Evaluate Usefulness of Cardio-Ankle Vascular Index in Japan
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy